New Clinical Facility in London, Ontario Accelerates Research and Innovation
VANCOUVER, British Columbia--(BUSINESS WIRE)--September 26, 2022--WellbeingDigital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA:SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGKSciences Inc. (“KGK”) has opened their new Clinical Research Center in London, Ontario, with the aim to accelerate their clients’ research and drug development needs in the nutraceutical, cannabinoid, hemp and psychedelic space.
KGK will host a grand opening ceremony on September 29, 2022 to officially open the new, state-of-the-art clinical research facility and celebrate being a leading contract research organization for over 25 years. The Company’s clinical research center empowers KGK to provide high-quality clinical research trials and expert regulatory support for clients in the nutraceutical, cannabis, hemp and psychedelic industries.
As a premium full-service contract research organization, KGK is dedicated to providing clinical trial research that meets the highest quality standards. Led by a team of scientific research and regulatory experts, KGK combines cutting-edge clinical science with industry expertise to design clinical trial and claim substantiation strategies customized to meet the needs of our clients.Having over 150 publications, the company is continuously pushing study designs and measurement tools forward in the industry and were most recently published in Frontiers Journal speaking about the assessment and re-evaluation of clinical trial design.
“Our new research center, located in the heart of London, Ontario will draw upon the strength and heritage of applied research and innovation and will be an ongoing opportunity for groundbreaking research in the fields of nutraceuticals, cannabinoids, hemp and psychedelics with global partners, clients and academics, striving for excellence as we have done over the past 25years,” said Najla Guthrie, CEO of Wellbeing & KGK. “Our goal is to strengthen the fundamental research needed for global innovation and enable the creation of next-generation nutraceuticals and pharmaceuticals.”
Media interested in attending the opening should contact Natalie Dolphin (firstname.lastname@example.org; phone: 416-706-6364) by 12 p.m. ET on Thursday,September 29, 2022.
ABOUT KGK SCIENCE
Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over150 publications, executed over 400 clinical trials across more than 40 indications, amassed25,000 participants in its database and collected 10 million data points. For additional information, please visit kgkscience.com.
ABOUT WELLBEING DIGITAL SCIENCES
Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.
On behalf of:
Chief Executive Officer
WELLBEING DIGITAL SCIENCES
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law.Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
For further information, please contact:
VP of Marketing & Investment Relations